Table 1.
Personal and laboratory findings of 101 cases of with influenza in the non-pneumonia and pneumonia groups
| Patients | Non-pneumonia group (n = 37) | Pneumonia group (n = 64) | P-value | |
|---|---|---|---|---|
| Age (years) | 56 (46–67) | 56 (37–71.5) | 56 (50–67) | 0.377 |
| Sex (male) | 62 (61.39%) | 21 (56.76%) | 41 (64.06%) | 0.467 |
| Length of stay in hospital (d) | 13 (7.5–21) | 9 (6.5–17) | 15 (9.25–26) | 0.003** |
| Underlying disease | ||||
| Hypertension | 30 (29.7%) | 8 (21.62%) | 22 (34.38%) | 0.177 |
| Diabetes | 21 (20.79%) | 10 (27.03%) | 11 (17.19%) | 0.240 |
| Liver diseases | 19 (18.81%) | 8 (21.62%) | 11 (17.19%) | 0.580 |
| Cardiovascular diseases | 10 (9.9%) | 2 (5.41%) | 8 (12.5%) | 0.250 |
| Respiratory diseases | 7 (6.93%) | 2 (5.41%) | 5 (7.81%) | 0.646 |
| Kidney diseases | 18 (17.82%) | 7 (18.92%) | 11 (17.19%) | 0.827 |
| Tumor | 28 (27.72%) | 10 (27.03%) | 18 (28.13%) | 0.905 |
| Cerebrovascular diseases | 6 (5.94%) | 0 (0%) | 6 (9.38%) | 0.138 |
| Respiratory virus | ||||
| Influenza A(Undifferentiated) | 81 (80.20%) | 25 (67.58%) | 56 (87.50%) | 0.031* |
| Influenza B | 20 (19.80%) | 12 (32.42%) | 8 (12.50%) | 0.031* |
| Symptom | ||||
| Cough | 71 (70.3%) | 21 (56.76%) | 50 (78.13%) | 0.024* |
| Sore throat | 7 (6.93%) | 4 (10.81%) | 3 (4.69%) | 0.447 |
| Diarrhea | 5 (4.95%) | 2 (5.41%) | 3 (4.69%) | 1.000 |
| Dyspnea | 20 (19.87%) | 1 (2.70%) | 19 (29.70%) | 0.001** |
| Chill | 10 (9.9%) | 3 (8.11%) | 7 (10.94%) | 0.910 |
| Runny nose | 4 (3.96%) | 1 (2.70%) | 3 (4.69%) | 1.000 |
| Muscle soreness | 6 (5.94%) | 2 (5.41%) | 4 (6.25%) | 1.000 |
| Laboratory indicators | ||||
| WBC (× 109 L−1) | 5.8 (3.7–7.9) | 5.3 (3.45–7.00) | 6.15 (4.23–8.28) | 0.077 |
| Neutrophil ratio (%) | 73.1 (56.3–85.6) | 61.3 (48.25–72.80) | 78.2 (66.58–88.15) | < 0.001*** |
| Lymphocyte ratio (%) | 14.7 (8.6–30.6) | 26.3 (14.65–38.1) | 13.5 (7.45–22.68) | < 0.001*** |
| CRP (mg/L) | 25.69 (9.10–73.85) | 16.85 (7.305–29.485) | 33.13 (11.73–102.98) | 0.001** |
| ALT (U/L) | 22 (13–40) | 69 (49–94.5) | 66.5 (56.25–84.75) | 0.231 |
| AST (U/L) | 30 (20–50) | 66.8 (59.3–70.8) | 59 (50.525–64.025) | 0.255 |
| LDH (U/L) | 265 (203–354) | 61 (35.50–130.50) | 60.5 (29.75–172.75) | 0.005** |
| CK (U/L) | 61 (33–166) | 20 (10–39.5) | 22 (14–45.5) | 0.913 |
| Cr (U/L) | 67 (53.5–88) | 27 (18–42.5) | 32 (20.75–51.25) | 0.871 |
| Total protein level (g/L) | 61.2 (53.25–67.4) | 223 (173–272) | 282.5 (225.25–383.75) | < 0.001*** |
| Urea nitrogen(mmol/l) | 5.78 (3.81–8.78) | 4.69 (3.44–7.05) | 6.57 (4.22–9.56) | 0.023* |
| Treatment | ||||
| Antiviral | 83 (82.18%) | 28 (75.68%) | 55 (85.94%) | 0.194 |
| Antibiotic | 87 (86.14%) | 26 (70.27%) | 61 (95.31%) | < 0.001*** |
| Glucocorticoid | 42 (41.58%) | 5 (13.51%) | 37 (57.81%) | < 0.001*** |
| Antifungal | 27 (26.73%) | 3 (8.11%) | 24 (37.5%) | 0.001** |
| Prognosis | ||||
| Invasive mechanical ventilation | 13 (12.87%) | 0 (0%) | 13 (20.31%) | 0.009** |
| ECMO | 1 (0.99%) | 0 (0%) | 1 (1.56%) | 1.000 |
| ICU admission | 12 (11.88%) | 0 (0%) | 12 (18.75%) | 0.013** |
| 90-day mortality | 11 (10.89%) | 0 (0%) | 11 (17.19%) | 0.019** |
WBC, white blood cell; CRP, C-reactive protein; ALT, alanine aminotransferase; AST, aspartate aminotransferase; CK, creatine kinase; LDH, lactate dehydrogenase; Cr, Creatinine; ECMO, Extracorporeal Membrane Oxygenation
Significant differences between non-pneumonia and pneumonia groups are indicated by asterisks
(*: P < 0.05; **: P < 0.01; ***: P < 0.001)